ncRNADetailInformation

Detail Information
Functional analysis

miRNA name

pre-miRNA

family

pre-miRNA Sequence

mature-miRNA

mature sequence

pre-miRNA description

let-7g

MI0000433	MIPF0000002	AGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCA	MIMAT0000414 hsa-let-7g-5p	UGAGGUAGUAGUUUGUACAGUU	let-7g-3p cloned in has a 1 nt 3' extension (U), which is incompatiblewith the genome sequence.
MI0000433	MIPF0000002	AGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCA	MIMAT0004584 hsa-let-7g-3p	CUGUACAGGCCACUGCCUUGC	let-7g-3p cloned in has a 1 nt 3' extension (U), which is incompatiblewith the genome sequence.
MI0000137	MIPF0000002	CCAGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCAGG	MIMAT0000121 mmu-let-7g-5p	UGAGGUAGUAGUUUGUACAGUU	The mature sequence reported in has a 3' terminal A residue, which isincompatible with the reported precursor sequence from and in thisentry. The mature sequence shown here represents the most commonly clonedform from large-scale cloning studies .
MI0000137	MIPF0000002	CCAGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCAGG	MIMAT0000121 mmu-let-7g-5p	UGAGGUAGUAGUUUGUACAGUU	The mature sequence reported in has a 3' terminal A residue, which isincompatible with the reported precursor sequence from and in thisentry. The mature sequence shown here represents the most commonly clonedform from large-scale cloning studies .
MI0000137	MIPF0000002	CCAGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCAGG	MIMAT0000121 mmu-let-7g-5p	UGAGGUAGUAGUUUGUACAGUU	The mature sequence reported in has a 3' terminal A residue, which isincompatible with the reported precursor sequence from and in thisentry. The mature sequence shown here represents the most commonly clonedform from large-scale cloning studies .
MI0000137	MIPF0000002	CCAGGCUGAGGUAGUAGUUUGUACAGUUUGAGGGUCUAUGAUACCACCCGGUACAGGAGAUAACUGUACAGGCCACUGCCUUGCCAGG	MIMAT0000121 mmu-let-7g-5p	UGAGGUAGUAGUUUGUACAGUU	The mature sequence reported in has a 3' terminal A residue, which isincompatible with the reported precursor sequence from and in thisentry. The mature sequence shown here represents the most commonly clonedform from large-scale cloning studies .

link to database

TargetScanS 6.2 | MicroCosm | microRNA.org | miRNAMap 2.0

Interacted genes from RAID,miRTarBase

IL13,HMGB1,BACH1,KRASP1,HIST1H1E,OPRM1,COL1A2,SFT2D1,CCND1,RAB21,HMGA2,MAP3K1,RPL12,DCAF8,KRAS
more » IL13,HMGB1,BACH1,KRASP1,HIST1H1E,OPRM1,COL1A2,SFT2D1,CCND1,RAB21,HMGA2,MAP3K1,RPL12,DCAF8,KRAS,RANBP2,TRIM71,SART3,BMI1,MYC,IGF2BP1,FAS,CDKN2A,MAGED1,BCL2L1,GAB2,EEF1A1,TBC1D9,LIN28A,CDC34,IL6,DICER1,CASP3,RRM2,BRD1,FN1,UBE3C,AKAP11,SOCS1,Olr1

KEGG pathways enriched for interacted genes

pathway name

pathway description

target genes enrich in pathway

p-value

hsa05220	Chronic myeloid leukemia	CCND1,BCL2L1,GAB2,CDKN2A,KRAS,MYC,	7.95E-6
hsa05200	Pathways in cancer	CCND1,FAS,BCL2L1,CDKN2A,FN1,KRAS,IL6,CASP3,MYC,	1.74E-5
hsa04115	p53 signaling pathway	CCND1,FAS,CDKN2A,RRM2,CASP3,	1.20E-4
hsa04630	Jak-STAT signaling pathway	CCND1,IL13,BCL2L1,SOCS1,IL6,MYC,	2.63E-4
hsa05219	Bladder cancer	CCND1,CDKN2A,KRAS,MYC,	5.41E-4

hsa05212	Pancreatic cancer	CCND1,BCL2L1,CDKN2A,KRAS,	2.61E-2
hsa05210	Colorectal cancer	CCND1,KRAS,CASP3,MYC,	4.04E-2
hsa05222	Small cell lung cancer	CCND1,BCL2L1,FN1,MYC,	4.04E-2
hsa05216	Thyroid cancer	CCND1,KRAS,MYC,	5.59E-2
hsa04120	Ubiquitin mediated proteolysis	CDC34,MAP3K1,SOCS1,UBE3C,	1.55E-1
hsa05213	Endometrial cancer	CCND1,KRAS,MYC,	1.73E-1
hsa04010	MAPK signaling pathway	FAS,MAP3K1,KRAS,CASP3,MYC,	1.84E-1
hsa05223	Non-small cell lung cancer	CCND1,CDKN2A,KRAS,	1.86E-1
hsa05221	Acute myeloid leukemia	CCND1,KRAS,MYC,	2.12E-1
hsa05214	Glioma	CCND1,CDKN2A,KRAS,	2.48E-1
hsa05218	Melanoma	CCND1,CDKN2A,KRAS,	3.10E-1
hsa04664	Fc epsilon RI signaling pathway	IL13,GAB2,KRAS,	3.69E-1
hsa04210	Apoptosis	FAS,BCL2L1,CASP3,	4.50E-1
hsa04722	Neurotrophin signaling pathway	MAGED1,MAP3K1,KRAS,	8.42E-1
hsa04110	Cell cycle	CCND1,CDKN2A,MYC,	8.54E-1
hsa04650	Natural killer cell mediated cytotoxicity	FAS,KRAS,CASP3,	9.49E-1

Gene ontology terms enriched for interacted genes

GO terms

GO terms description

target genes enrich in GO term

p-value

GO:0008637	apoptotic mitochondrial changes	MAP3K1,BCL2L1,CDKN2A,CASP3,MYC,	1.26E-6
GO:0050864	regulation of B cell activation	FAS,IL13,CDKN2A,IL6,CASP3,	9.65E-6
GO:0042127	regulation of cell proliferation	CCND1,MAGED1,IL13,OPRM1,BCL2L1,BMI1,CDKN2A,KRAS,IL6,CASP3,MYC,	2.66E-5
GO:0010033	response to organic substance	CCND1,FAS,BCL2L1,DICER1,KRAS,SOCS1,IL6,LIN28A,CASP3,MYC,	8.46E-5
GO:0044265	cellular macromolecule catabolic process	CDC34,MAP3K1,EIF2C1,CDKN2A,SOCS1,UBE3C,LIN28A,CASP3,MYC,RANBP2,	8.83E-5

GO:0010605	negative regulation of macromolecule metabolic process	BCL2L1,HMGB1,DICER1,EIF2C1,IGF2BP1,CDKN2A,SOCS1,IL6,LIN28A,MYC,	9.71E-5
GO:0006915	apoptosis	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,KRAS,IL6,CASP3,MYC,	1.46E-4
GO:0009057	macromolecule catabolic process	CDC34,MAP3K1,EIF2C1,CDKN2A,SOCS1,UBE3C,LIN28A,CASP3,MYC,RANBP2,	1.56E-4
GO:0012501	programmed cell death	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,KRAS,IL6,CASP3,MYC,	1.62E-4
GO:0042981	regulation of apoptosis	MAGED1,FAS,MAP3K1,BCL2L1,HMGB1,CDKN2A,KRAS,IL6,CASP3,MYC,	1.94E-4
GO:0043067	regulation of programmed cell death	MAGED1,FAS,MAP3K1,BCL2L1,HMGB1,CDKN2A,KRAS,IL6,CASP3,MYC,	2.09E-4
GO:0010941	regulation of cell death	MAGED1,FAS,MAP3K1,BCL2L1,HMGB1,CDKN2A,KRAS,IL6,CASP3,MYC,	2.15E-4
GO:0010608	posttranscriptional regulation of gene expression	DICER1,EIF2C1,IGF2BP1,CDKN2A,IL6,LIN28A,	2.23E-4
GO:0043066	negative regulation of apoptosis	FAS,BCL2L1,HMGB1,KRAS,IL6,CASP3,MYC,	3.08E-4
GO:0043069	negative regulation of programmed cell death	FAS,BCL2L1,HMGB1,KRAS,IL6,CASP3,MYC,	3.32E-4
GO:0060548	negative regulation of cell death	FAS,BCL2L1,HMGB1,KRAS,IL6,CASP3,MYC,	3.37E-4
GO:0007005	mitochondrion organization	MAP3K1,BCL2L1,CDKN2A,CASP3,MYC,	4.73E-4
GO:0008219	cell death	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,KRAS,IL6,CASP3,MYC,	4.91E-4
GO:0016265	death	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,KRAS,IL6,CASP3,MYC,	5.14E-4
GO:0051249	regulation of lymphocyte activation	FAS,IL13,CDKN2A,IL6,CASP3,	6.17E-4
GO:0008284	positive regulation of cell proliferation	CCND1,IL13,BCL2L1,BMI1,KRAS,IL6,MYC,	7.07E-4
GO:0043065	positive regulation of apoptosis	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,CASP3,MYC,	8.63E-4
GO:0043068	positive regulation of programmed cell death	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,CASP3,MYC,	8.94E-4
GO:0035195	gene silencing by miRNA	DICER1,EIF2C1,LIN28A,	9.13E-4
GO:0010942	positive regulation of cell death	MAGED1,FAS,MAP3K1,BCL2L1,CDKN2A,CASP3,MYC,	9.16E-4
GO:0002694	regulation of leukocyte activation	FAS,IL13,CDKN2A,IL6,CASP3,	9.48E-4
GO:0050869	negative regulation of B cell activation	FAS,CDKN2A,CASP3,	1.02E-2
GO:0006309	DNA fragmentation involved in apoptosis	CDKN2A,CASP3,MYC,	1.14E-2
GO:0051384	response to glucocorticoid stimulus	CCND1,FAS,KRAS,IL6,	1.14E-2
GO:0050865	regulation of cell activation	FAS,IL13,CDKN2A,IL6,CASP3,	1.15E-2
GO:0042325	regulation of phosphorylation	CCND1,MAP3K1,CDKN2A,KRAS,SOCS1,IL6,CASP3,	1.30E-2
GO:0050670	regulation of lymphocyte proliferation	IL13,CDKN2A,IL6,CASP3,	1.37E-2
GO:0035194	posttranscriptional gene silencing by RNA	DICER1,EIF2C1,LIN28A,	1.40E-2
GO:0016441	posttranscriptional gene silencing	DICER1,EIF2C1,LIN28A,	1.40E-2
GO:0001836	release of cytochrome c from mitochondria	BCL2L1,CASP3,MYC,	1.40E-2
GO:0032944	regulation of mononuclear cell proliferation	IL13,CDKN2A,IL6,CASP3,	1.42E-2
GO:0070663	regulation of leukocyte proliferation	IL13,CDKN2A,IL6,CASP3,	1.42E-2
GO:0032268	regulation of cellular protein metabolic process	CCND1,MAP3K1,EIF2C1,IGF2BP1,CDKN2A,SOCS1,IL6,	1.42E-2
GO:0031960	response to corticosteroid stimulus	CCND1,FAS,KRAS,IL6,	1.47E-2
GO:0051174	regulation of phosphorus metabolic process	CCND1,MAP3K1,CDKN2A,KRAS,SOCS1,IL6,CASP3,	1.60E-2
GO:0019220	regulation of phosphate metabolic process	CCND1,MAP3K1,CDKN2A,KRAS,SOCS1,IL6,CASP3,	1.60E-2
GO:0048545	response to steroid hormone stimulus	CCND1,FAS,KRAS,SOCS1,IL6,	1.62E-2
GO:0006921	cell structure disassembly during apoptosis	CDKN2A,CASP3,MYC,	1.68E-2
GO:0009314	response to radiation	CCND1,BCL2L1,KRAS,CASP3,MYC,	1.88E-2
GO:0000737	DNA catabolic process, endonucleolytic	CDKN2A,CASP3,MYC,	2.14E-2
GO:0030262	apoptotic nuclear changes	CDKN2A,CASP3,MYC,	2.14E-2
GO:0030888	regulation of B cell proliferation	IL13,CDKN2A,CASP3,	2.49E-2
GO:0009725	response to hormone stimulus	CCND1,FAS,BCL2L1,KRAS,SOCS1,IL6,	2.69E-2
GO:0009628	response to abiotic stimulus	CCND1,MAP3K1,BCL2L1,KRAS,CASP3,MYC,	2.73E-2
GO:0031047	gene silencing by RNA	DICER1,EIF2C1,LIN28A,	3.45E-2
GO:0001776	leukocyte homeostasis	FAS,IL6,CASP3,	4.09E-2
GO:0009719	response to endogenous stimulus	CCND1,FAS,BCL2L1,KRAS,SOCS1,IL6,	4.11E-2
GO:0044093	positive regulation of molecular function	CCND1,OPRM1,MAP3K1,CDKN2A,KRAS,IL6,MYC,	4.13E-2
GO:0031399	regulation of protein modification process	CCND1,MAP3K1,CDKN2A,SOCS1,IL6,	7.53E-2
GO:0006997	nucleus organization	CDKN2A,CASP3,MYC,	8.39E-2
GO:0022411	cellular component disassembly	CDKN2A,CASP3,MYC,	8.71E-2
GO:0051250	negative regulation of lymphocyte activation	FAS,CDKN2A,CASP3,	9.03E-2
GO:0000079	regulation of cyclin-dependent protein kinase activity	CCND1,CDKN2A,CASP3,	9.03E-2
GO:0000082	G1/S transition of mitotic cell cycle	CCND1,CDC34,CDKN2A,	9.68E-2
GO:0016458	gene silencing	DICER1,EIF2C1,LIN28A,	9.68E-2
GO:0006917	induction of apoptosis	MAGED1,FAS,CDKN2A,CASP3,MYC,	9.97E-2
GO:0002695	negative regulation of leukocyte activation	FAS,CDKN2A,CASP3,	1.00E-1
GO:0012502	induction of programmed cell death	MAGED1,FAS,CDKN2A,CASP3,MYC,	1.00E-1

KEGG pathways and Gene Ontology terms enriched for the interacted genes of ncRNA from RAID and miRTarBase.

disease name	related genes	p-value